(Q44992743)

English

HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

V Guarneri

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

C Bengala

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

C Orlandini

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

A Gennari

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

S Donati

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

D Campani

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

P Collecchi

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

M Maur

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

P F Conte

9

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

language of work or name

0 references

publication date

1 September 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

413-417

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704619

0 references

p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

21 January 2018

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy for breast cancer: the French PEGASE experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704619

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704619

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44992743&oldid=2060712030"